Investigating how the loss of ARID1A and estrogen signaling affects endometrial cancer
The combined role of ARID1A loss and estrogen signaling in endometrial cancer
This study is looking at how changes in a specific gene called ARID1A and the hormone estrogen affect the growth of endometrial cancer, with the goal of finding new ways to treat this common type of cancer in women.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11047692 on NIH RePORTER |
What this research studies
This research focuses on understanding the relationship between the loss of the ARID1A gene and estrogen signaling in endometrial cancer, which is the most common gynecological cancer in the U.S. The study will utilize advanced 3D cell culture techniques and animal models to explore how these factors contribute to cancer progression. By examining the interactions between ARID1A mutations and estrogen receptor activity, the research aims to identify potential vulnerabilities in cancer cells that could be targeted for treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with endometrial cancer, particularly those with endometrioid tumors that may have ARID1A mutations.
Not a fit: Patients with non-endometrial cancers or those without ARID1A mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating endometrial cancer by targeting specific vulnerabilities related to ARID1A loss and estrogen signaling.
How similar studies have performed: Previous research has shown promising results in understanding the role of estrogen signaling in endometrial cancer, but the specific focus on ARID1A loss in this context is relatively novel.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Gertz, Jason — University of Utah
- Study coordinator: Gertz, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.